Learning on the go with APNA online learning
APNA will be conducting a webinar on Tuesday, 27 February, from 6:30-7:30pm AEDT.
The first respiratory syncytial virus (RSV) vaccine, AREXVY, has been approved in Australia and will soon be available for older adults to protect them in advance of the 2024 virus season. Following the recent announcement of regulatory approval for the vaccine in Australia, for the purpose of actively immunising individuals aged 60 and above to prevent lower respiratory tract disease caused by RSV.
This webinar aims to assist healthcare providers in ensuring the proper use and safe administration for eligible patients.